Iran launches domestic manufacture of anti-hemophilia drug (Prokonvertin or FactorVII/NovoSeven) and monoclonal antibodies

Iran is increasingly strengthened themselves with self-sufficient in many fields. In the pharmaceutical field too, Iran has managed to achieve self-sufficiency.

Monday, February 6, 2012 morning, Iranian President Mahmoud Ahmadinejad inaugurated manufacturer of Prokonvertin drugs (FactorVII/NovoSeven) and new protein. Both include a new generation of biotech drugs. – Iran launches domestic manufacture of anti-hemophilia drug (Prokonvertin or FactorVII/NovoSeven) and monoclonal antibodies -

Inauguration of the new generation of drug manufacturers Iran was held at the Corporate Environmental Medicine Ryzun' in the city Garmdare, Alborz province, and attended a number of pharmaceutical experts. With the start of production of these drugs, Iran could save annually about 100 million U.S. dollars. – Iran launches domestic manufacture of anti-hemophilia drug (Prokonvertin or FactorVII/NovoSeven) and monoclonal antibodies -

Prokonvertin (Factor VII / Novo Seven) is a drug to treat hemophilia, whereas previously Iran every year has to pay around 50 million dollars to import these drugs.

Meanwhile, a new protein specific monoclonal antibody is another product whose creation was inaugurated by Ahmadinejad.

Biotechnology drug products made Iran become the second country after Denmark that successfully produce prokonvertin specifically for people with hemophilia (a genetic blood disorder).


Meanwhile, Iran's success in producing monoclonal antibodies make this country become the ninth country in the world that have been able to produce antibodies of this type.

In the inauguration of a new generation of drugs Iran, Ahmadinejad is also reviewing the manufacturer and were briefed about the process of making biotech drugs.